Permeation-enhancing effects of chitosan formulations on recombinant hirudin-2 by nasal delivery in vitro and in vivo

Acta Pharmacologica Sinica

Volumn 26, Issue 11, 2005, Pages 1402-1408

  Zhang, Yu Jie ^a,b   Ma, Chang Hua ^c   Lu, Wan Liang ^c   Zhang, Xuan ^c   Wang, Xiao Liang ^c   Sun, Jian Ning ^c   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c NONE

Author keywords

Bioavailability; Chitosan formulation; Ciliotoxicity; Enhancer; Hirudin; Nasal absorption; Permeability

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CHITOSAN; DODECYL SULFATE SODIUM; EDETIC ACID; FLUORESCEIN ISOTHIOCYANATE; GLYCYRRHIZIC ACID; LAUROCAPRAM; MENTHOL; PHOSPHATIDYLCHOLINE; POLIDOCANOL; POLYSORBATE 80; RECOMBINANT HIRUDIN; RECOMBINANT HIRUDIN 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CILIATED EPITHELIUM; CONTROLLED STUDY; CYTOTOXICITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG PENETRATION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; NOSE MUCOSA; PALATE; RABBIT; RAT; TOAD;

ABSORPTION; ADMINISTRATION, INTRANASAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BUFO BUFO; CHITOSAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FLUORESCEIN-5-ISOTHIOCYANATE; HIRUDINS; MALE; NASAL MUCOSA; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS;

EID: 27744602761     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2005.00174.x     Document Type: Article

References (29)

1. Walenga JM, Pifarre R, Fareed J. Recombinant hirudin as an antithrombotic agent. Drugs Future 1990; 15: 267-80.
2. Markwardt F, Fink G, Kaiser B, Klocking HP, Nowak G, Richter M, et al. Pharmacological survey of recombinant hirudin. Pharmazie 1988; 43: 202-7.
3. Doutremepuich C, Deharo E, Guyot M, Lalanne MC, Walenga JM, Farced J. Antithrombotic activity of recombinant hirudin in rat: a comparative study with heparin. Thrombos Res 1989; 54: 435-45.
4. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res 1994; 74: 1-23.
5. Markwardt F. Prospective clinical use of hirudin as an anticoagulant. Biomed Prog 1990; 3: 19-23.
6. Han YM, Lu YF, Wang ZH. Studies on the effects of anticoagulant and anti-thrombin after duodenal administration of recombinant hirudin in rats. Chin J Hematol 1999; 20: 483-4.
7. Yang XY, Wang XT, Zhang XN, Zhang Q. Gastrointestinal absorption of recombinant hirudin-2 in rats. J Pharmacol Exp Ther 2004; 308: 774-9.
8. Schipper NG, Olsson S, Hoogstraate JA, deBoer AG, Varum KM, Artursson P. Chitosan as absorption enhancers for poorly absorbable drugs. 2: Mechanism of absorption enhancement. Pharm Res 1997; 14: 923-9.
9. Aspden TJ, Mason JD, Jones NS, Lowe J, Skaugrud O, Ilium L. Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J Pharm Sci 1997; 86: 509-13.
10. Jiang XG, Cui JB, Fang XL, Wei Y, Xi NZ. Toxicity of drugs on nasal mucocilia and method of its evaluation. Acta Pharm Sin 1995; 30: 848-53.
11. 1 Wang HD, Zhou SH. Marking techniques of biomedicine. Beijing: People's Medical Publishing House; 1995.
12. Griessbach U, Stürzebecher J, Markwardt F. Assay of hirudin in plasma using a chromogenic thrombin substrate. Thromb Res 1985; 37: 347-50.
13. Hosoya K, Kubo H, Natsume H, Sugibayashi K, Morimoto Y. Evaluation of enhancers to increase nasal absorption using chamber technique. Biol Pharm Bull 1994; 17: 316-22.
14. Chandler SG, Ilium L, Tomas NM. Nasal absorption in rats. II Effect of enhancers on insulin absorption and nasal histology. Int J Pharm 1991; 76: 61-70.
15. Temesvari LA, Bush JM, Peterson MD, Novak KD, Titus MA, Cardelli JA. Examination of the endosomal and lysosomal pathways in Dictyostelium discoideum myosin I mutants. J Cell Sci 1996; 109: 663-73.
16. Ilium L. Chitosan and its use as a pharmaceutical excipient. Pharm Res 1998; 15: 1326-31.
17. Ilium L, Farraj NF, Davis SD. Chitosan as a novel basal delivery system for peptide drugs. Pharm Res 1994; 11: 1186-9.
18. Shojaei AH. Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharm Sci 1998; 1: 15-30.
19. Rege BD, Kao JP, Polli JE. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci 2002; 16: 237-46.
20. Sugibayashi K, Nakayama S, Seki T, Hosoya K, Morimoto YJ. Mechanism of skin penetration-enhancing effect by laurocapram. Pharm Sci 1992; 81: 58-64.
21. Wang GS, Zabner J, Deering C, Launspach J, Shao JQ, Bodner M. Increasing epithelial junction permeability enhances gene transfer to airway epithelia in vivo. Am J Respir Cell Mol Biol 2000; 22: 129-38.
22. Marttin E, Verhoef JC, Cullander C, Romeijn SG, Nagelkerke JF, Merkus FW. Confocal laser scanning microscopic visualization of the transport of dextrans after nasal administration to rats: effects of absorption enhancer. Pharm Res 1997; 14: 631-7.
23. 3 Yang T, Hussain A, Paulson J, Abbruscato TJ, Ahsan F. Cyclodextrins in nasal delivery of low-molecular-weight heparins: in vivo and in vitro studies. Pharm Res 2004; 21: 1127-36.
24. Merkus FW, Verhoef JC, Marttin E, Romeijn SG, van der Kuy PH, Hermens WA, et al. Cyclodextrins in nasal drug delivery. Adv Drug Deliv Rev 1999; 36: 41-57.
25. Yu SY, Zhao Y, Wu FL, Zang X, Lu WL, Zhang H. Nasal insulin delivery in the chitosan solution: in vitro and in vivo studies. Int J Pharm 2004; 281: 11-23.
26. Maitani Y, Nakamura K, Suenaga H, Kamata K, Takayama K, Nagai T. The effect of soybean-derived sterylglucoside and β-sitosterol β-D-glucoside on nasal absorption in rabbits. Int J Pharm 2000; 200: 17-26.
27. Kaplun-Frischoff Y, Touitou E. Testosterone skin permeation enhancement by menthol through formation of eutectic with drug and interaction with skin lipids. J Pharm Sci 1997; 86: 1394-9.
28. Sakai M, Imai T, Ohtake H, Azuma H, Otagiri M. Effects of absorption enhancers on cytoskeletal actin filaments in Caco-2 cell monolayers. Life Sci 1998; 63: 45-54.
29. Sakai M, Imai T, Ohtake H, Azuma H, Otagiri M. Simultaneous use of sodium deoxycholate and dipotassium glycyrrhizinate enhances the cellular transport of poorly absorbed compounds across Caco-2 cell monolayers. J Pharm Biomed Anal 2004; 36: 915-9.